cryptocurrency digital currency, snippets

Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Shanghai's action plan for mergers and acquisitions is still very strong! Three years to cultivate 10 head companies, forming a scale of 300 billion mergers and acquisitions, which clearly accelerate the merger of securities companies and build a first-class investment bank. This is a semiconductor leader, a pharmaceutical leader, a new material leader, a brokerage leader, etc., which directly benefits Shanghai local stocks and pays attention to Shanghai's advantages. This time, the merger with assets exceeding 2 trillion is clearly activated, which shows great determination.Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;

After the market closed, the Shanghai Municipal Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027). Among them, it is proposed to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan. In addition, the plan also mentioned that the merger of securities companies should be accelerated to build a first-class investment bank.Easy to change the world: shareholders intend to reduce their holdings by no more than 3.05% in total;China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.

Yiming Food issued a suggestive announcement on the risk of stock trading. Since November 26, 2024, the company's stock has been trading daily for 11 consecutive times, with a cumulative turnover rate of 66.9%, which is a risk of a sharp decline in the short term. At the same time, several major shareholders reduced their holdings of shares not exceeding 1% of the total share capital. As of the close of December 10, 2024, the three partnership platforms reduced their holdings by 138,200 shares today.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.First, heavy! Shanghai merger and reorganization action plan announced